Definitive Contract HHSO100201500027C

Award Date 9/29/15
Potential Completion Date 9/28/25
Potential Value $236M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Madison, WI 53719, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed

This is a federal contract awarded by the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Stratatech Corporation, a subsidiary of the global pharmaceutical company Mallinckrodt Plc. The $235,674,165.70 cost-plus-fixed-fee contract, awarded on September 29, 2015, is for the development of cell-based skin substitutes for the definitive care of burn injuries. The contract has a completion date of September 28, 2025. Stratatech Corporation is a foreign-owned, for-profit organization that has previously received federal grant funding for the development of regenerative medicine and tissue engineering products. This contract does not have a set-aside designation. In addition to this contract award, Stratatech Corporation also holds two active federal Indefinite Delivery Vehicle (IDV) contracts with the Department of Veterans Affairs to provide pharmaceutical and hematology-related products to VA medical facilities.

Generated 8/20/24, 9:03 AM